PHarmaceutical tech@2x
  • News

    Most Read

    • Merck to discontinue development of two Covid-19 vaccine candidates
    • Moderna’s Covid-19 vaccine effective against emerging variants in new study
    • Elasmogen identifies potential vaccine candidates to fight Covid-19

    Most Recent

    Drug Development

    Merck to discontinue development of two Covid-19 vaccine candidates

    26 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Genomics: Technology Trends
    • A new hope for slowing disability in MS
    • Covid-19 vaccine rollouts begin worldwide – leading macroeconomic influencers

    Most Recent

    Genomics: Technology Trends

    25 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
      • Respiratory

    Most Read

    • Merck to discontinue development of two Covid-19 vaccine candidates
    • GlobalData Epidemiologist Report: Global Covid cases pass 99.3 million – US tops 25 million
    • Moderna’s Covid-19 vaccine effective against emerging variants in new study

    Most Recent

    Drug Development

    Merck to discontinue development of two Covid-19 vaccine candidates

    26 Jan 2021
  • Themes
  • Deals

    Most Read

    • Lilly acquires biotechnology company Prevail Therapeutics for $1.04bn
    • Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
    • Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

    Most Recent

    deal

    Lilly acquires biotechnology company Prevail Therapeutics for $1.04bn

    25 Jan 2021
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • CPL
    • TOTE® SYSTEMS
    • RSD

    Most Recent

    Drug Development

    CPL

    25 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Supply Chain
    • Drug Development
    • Manufacturing
    • Diseases
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Diseases
      • Oncology
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Powder Handling
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Novartis and Incyte to trial Jakavi for Covid-19

Novartis and Incyte to trial Jakavi for Covid-19

Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase...

3 April 2020
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline

Vertex-Semma $950m acquisition: bringing diabetes into the pipeline

Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics...

4 September 2019
Maze Therapeutics raises $191m to support genetic research

Maze Therapeutics raises $191m to support genetic research

Third Rock Ventures has launched Maze Therapeutics, a start-up focused on translating genetic insights into new medicines.  

1 March 2019
GE to divest its Biopharma business to Danaher for $21.4bn

GE to divest its Biopharma business to Danaher for $21.4bn

US-based conglomerate General Electric (GE) has entered into a definitive agreement to divest its Biopharma...

26 February 2019
Outcome-based payment system could expedite cancer treatment

Outcome-based payment system could expedite cancer treatment

A new report by Cancer Research UK has concluded that a new drug payment system,...

22 February 2019
FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis

FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis

The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted...

20 February 2019
No-deal Brexit could put UK patients at risk of fake medicines

No-deal Brexit could put UK patients at risk of fake medicines

The Association of the British Pharmaceutical Industry (ABPI), a trade group representing drugmakers in the...

8 February 2019
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology

Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology

Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR)...

7 February 2019
US Government’s new rule targets drug industry’s rebate system

US Government’s new rule targets drug industry’s rebate system

US Department of Health & Human Services (HHS) has proposed a new rule to end...

1 February 2019
UK unveils plan to tackle growing antimicrobial resistance

UK unveils plan to tackle growing antimicrobial resistance

The UK Government has set out a plan to fight antimicrobial resistance (AMR) in the...

24 January 2019

Latest News

Drug Development

Merck to discontinue development of two Covid-19 vaccine candidates

26 Jan 2021
Drug Development

Moderna’s Covid-19 vaccine effective against emerging variants in new study

25 Jan 2021
Drug Development

Elasmogen identifies potential vaccine candidates to fight Covid-19

25 Jan 2021
Technology

Telemedicine to benefit the most from remote patient monitoring tools: Poll

25 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
logo-horizontal

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms & Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more